A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer.

[1]  D. Gaudet,et al.  Immunosuppression Modulates Immune Responses to AAV Capsid in Human Subjects Undergoing Intramuscular Gene Transfer for Lipoprotein Lipase Deficiency , 2008 .

[2]  J. Kaplan,et al.  Cytotoxic T-Lymphocyte (CTL) responses to the transgene product and not AAV capsid protein limit transgene expression in mice , 2008 .

[3]  T. Kanda,et al.  Antibody-dependent enhancement of adeno-associated virus infection of human monocytic cell lines. , 2008, Virology.

[4]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[5]  P. Puthavathana,et al.  Role of Dendritic Cells in Antibody-Dependent Enhancement of Dengue Virus Infection , 2008, Journal of Virology.

[6]  K. High,et al.  Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  M. Feinberg,et al.  Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. , 2007, Virology.

[8]  E. Wherry,et al.  Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. , 2007, Blood.

[9]  R. Samulski,et al.  Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In Vivo , 2007, Journal of Virology.

[10]  Lili Wang,et al.  Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. , 2007, Human gene therapy.

[11]  Z. Xiang,et al.  Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  Marcela V Maus,et al.  CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.

[13]  Jin-Sung Lee,et al.  Recombinant adeno-associated virus mediated gene transfer in a mouse model for homocystinuria , 2006, Experimental & Molecular Medicine.

[14]  Z. Xiang,et al.  A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  D. Millington,et al.  Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia , 2006, Gene Therapy.

[16]  Sang-Jun Ha,et al.  Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. , 2006, Journal of immunology.

[17]  H. Morizono,et al.  Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  W. Chuang,et al.  AAV8‐mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease , 2006, The journal of gene medicine.

[19]  A. Ballabio,et al.  Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. , 2006, Human molecular genetics.

[20]  Rolf M. Zinkernagel,et al.  Antiviral antibody responses: the two extremes of a wide spectrum , 2006, Nature Reviews Immunology.

[21]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[22]  H. Ertl,et al.  Identification of mouse AAV capsid-specific CD8+ T cell epitopes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Theresa A. Storm,et al.  Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. , 2003, Blood.

[24]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[25]  L. Kaer,et al.  Critical contribution of liver natural killer T cells to a murine model of hepatitis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Russell,et al.  Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Z. Xiang,et al.  A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. , 1996, Virology.